These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28433713)

  • 1. Biased signaling at neural melanocortin receptors in regulation of energy homeostasis.
    Yang LK; Tao YX
    Biochim Biophys Acta Mol Basis Dis; 2017 Oct; 1863(10 Pt A):2486-2495. PubMed ID: 28433713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biased signaling initiated by agouti-related peptide through human melanocortin-3 and -4 receptors.
    Yang Z; Tao YX
    Biochim Biophys Acta; 2016 Sep; 1862(9):1485-94. PubMed ID: 27208795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive activity of neural melanocortin receptors.
    Tao YX; Huang H; Wang ZQ; Yang F; Williams JN; Nikiforovich GV
    Methods Enzymol; 2010; 484():267-79. PubMed ID: 21036237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocortin receptors as drug targets for disorders of energy balance.
    Adan RA; van Dijk G
    CNS Neurol Disord Drug Targets; 2006 Jun; 5(3):251-61. PubMed ID: 16787227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanocortin receptors as targets in the treatment of obesity.
    Lam DD; Farooqi IS; Heisler LK
    Curr Top Med Chem; 2007; 7(11):1085-1097. PubMed ID: 17584129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-Opiomelanocortin (POMC) Neurones, POMC-Derived Peptides, Melanocortin Receptors and Obesity: How Understanding of this System has Changed Over the Last Decade.
    Mountjoy KG
    J Neuroendocrinol; 2015 Jun; 27(6):406-18. PubMed ID: 25872650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 60 YEARS OF POMC: Regulation of feeding and energy homeostasis by α-MSH.
    Anderson EJ; Çakir I; Carrington SJ; Cone RD; Ghamari-Langroudi M; Gillyard T; Gimenez LE; Litt MJ
    J Mol Endocrinol; 2016 May; 56(4):T157-74. PubMed ID: 26939593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenoprofen-An Old Drug Rediscovered as a Biased Allosteric Enhancer for Melanocortin Receptors.
    Yuan XC; Tao YX
    ACS Chem Neurosci; 2019 Mar; 10(3):1066-1074. PubMed ID: 30168706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neural melanocortin receptors in obesity and related metabolic disorders.
    Girardet C; Butler AA
    Biochim Biophys Acta; 2014 Mar; 1842(3):482-94. PubMed ID: 23680515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
    Kühnen P; Krude H; Biebermann H
    Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction.
    Wikberg JE; Mutulis F
    Nat Rev Drug Discov; 2008 Apr; 7(4):307-23. PubMed ID: 18323849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin.
    Yuan XC; Tao YX
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feeding effects of melanocortin ligands--a historical perspective.
    Irani BG; Haskell-Luevano C
    Peptides; 2005 Oct; 26(10):1788-99. PubMed ID: 16046247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
    Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
    Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The melanocortin system in Fugu: determination of POMC/AGRP/MCR gene repertoire and synteny, as well as pharmacology and anatomical distribution of the MCRs.
    Klovins J; Haitina T; Fridmanis D; Kilianova Z; Kapa I; Fredriksson R; Gallo-Payet N; Schiöth HB
    Mol Biol Evol; 2004 Mar; 21(3):563-79. PubMed ID: 14694081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive receptor activity series: endogenous inverse agonists and constitutive receptor activity in the melanocortin system.
    Adan RA
    Trends Pharmacol Sci; 2006 Apr; 27(4):183-6. PubMed ID: 16500715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular signatures of human melanocortin receptors for ligand binding and signaling.
    Yang Y; Harmon CM
    Biochim Biophys Acta Mol Basis Dis; 2017 Oct; 1863(10 Pt A):2436-2447. PubMed ID: 28478228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity.
    Tao YX
    Mol Cell Endocrinol; 2005 Jul; 239(1-2):1-14. PubMed ID: 15975705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the development of melanocortin receptor selective ligands.
    Irani BG; Holder JR; Todorovic A; Wilczynski AM; Joseph CG; Wilson KR; Haskell-Luevano C
    Curr Pharm Des; 2004; 10(28):3443-79. PubMed ID: 15579046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Melanocortin-3 and -4 Receptors by Isoforms of Melanocortin-2 Receptor Accessory Protein 1 and 2.
    Ji RL; Tao YX
    Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.